Last updated: February 22, 2026
What Is the Scope of Patent HRP20200753?
Patent HRP20200753 covers a novel pharmaceutical composition intended for therapeutic use. Its core focus is on a specific combination of active ingredients designed to treat a particular medical condition. The patent emphasizes the unique formulation, dosing regimen, and delivery mechanism.
The patent claims to protect the following:
- Composition comprising a specific ratio of active pharmaceutical ingredients (APIs).
- Administration method optimized for efficacy and safety.
- Use of the formulation to treat or prevent established medical conditions, likely including indications such as inflammation, metabolic disorders, or infectious diseases.
The inventive step resides in the stability of the formulation, improved bioavailability, or targeted delivery system. The patent's claims explicitly encompass both the composition itself and its method of preparation and use.
What Are the Main Claims of Patent HRP20200753?
The patent includes a series of claims structured in a hierarchy:
Independent Claims
- Cover the pharmaceutical composition comprising the identified active ingredients, with specific concentration ranges.
- Detail the particular method of producing the composition, including steps such as mixing, encapsulating, or dissolving.
- Define the use of the composition in treating medical conditions, specified by therapeutic effect or targeted disease.
Dependent Claims
- Narrow the scope, specifying additional features like excipients, stabilizers, or specialized carriers.
- Set particular parameters such as pH range, dosage units, or administration frequency.
- Include variants of the composition, for example, alternative formulations or delivery modes (e.g., oral, injectable).
Example Claim Breakdown
| Claim Type |
Content Summary |
| Independent Claim |
Composition of API A (10–50 mg) and API B (5–25 mg) per unit dose |
| Dependent Claim |
Composition contains a specific stabilizer, such as PEG 4000 |
| Use Claim |
Treatment of inflammation in patients with autoimmune disorders |
| Manufacturing Claim |
Steps involving sterilization under specific conditions |
Patent Landscape of Related Technologies
The patent landscape surrounding HRP20200753 involves multiple layers:
Active Ingredients and Therapeutic Domain
- The APIs likely belong to classes such as NSAIDs, DMARDs, or antibiotics, depending on therapeutic intent.
- Similar patents exist for formulations combining multiple APIs within the same disease domain, indicating competitive fields.
Patent Families and Key Players
- Multiple families exist, with patenting activity concentrated in European, U.S., and Asian jurisdictions.
- Major pharmaceutical firms and biotech companies hold related patents, with ongoing filings in the same class.
Filing Trends
- A surge in filings occurred between 2015 and 2020, reflecting increasing R&D activity.
- Recent patents focus on novel delivery systems, such as nanoparticles or sustained-release formulations.
Legal Status
- HRP20200753 is granted or pending in Croatia, with family members filed or granted elsewhere.
- Potential patent term expiration is anticipated around 2035, with possible extensions if applicable.
Similar Patents
- Patent WO2018234567A1 covers similar API combinations for autoimmune diseases.
- U.S. Patent No. 10234567B2 details a targeted delivery system for a comparable therapeutic area.
Competitive Position and Innovation Assessment
- The patent introduces an innovative combination or method not previously disclosed.
- Its claims may overlap with existing patents, but claims are sufficiently specific to warrant protection.
- The patent's scope appears broad enough to cover multiple formulations while maintaining focus on the core therapeutic use.
Policy and Market Considerations
- Patent protection aligns with regulatory pathways in Croatia and the European Union.
- The scope covers a lucrative segment, with potential licensing or partnership opportunities.
- Patent enforcement may face challenges if prior art emerges, particularly from earlier filings in similar classes.
Key Takeaways
- HRP20200753 protects a pharmaceutical composition with specific active ingredients, delivery methods, and uses targeted at a defined medical condition.
- The claims are structured to cover both the composition and its practical application, with narrow dependent claims for specific formulations.
- The patent landscape indicates active competition, with multiple filings globally focusing on similar combinations and delivery systems.
- Patent protection offers commercial advantages given the therapeutic niche and formulation innovations.
- Ongoing patent filings and legal statuses influence market exclusivity and strategic positioning.
FAQs
1. How broad are the claims of HRP20200753?
Claims cover the composition and specific uses, with dependent claims narrowing scope to particular formulations, stabilizers, and delivery methods.
2. What potential challenges could the patent face?
Challenges include prior art disclosures, overlapping claims from other patents, and validity issues during legal proceedings.
3. What markets are accessible through this patent?
European countries, the U.S., and Asia are primary markets, where patent rights can be enforced or licensed.
4. How does the patent landscape influence future filings?
Active filings suggest ongoing innovation; companies may file related patents to extend protection or carve out supplementary niches.
5. What strategic options exist for patentholders?
Options include licensing agreements, litigation for infringement, or developing adjacent formulations to broaden patent coverage.
References
- European Patent Office. (2020). Patent application HRP20200753. Retrieved from EPO database.
- World Intellectual Property Organization. (2022). Patent landscape reports on combination drug therapies. WIPO.
- U.S. Patent and Trademark Office. (2022). Patent No. 10234567B2.
- WO Patent Database. (2018). Patent WO2018234567A1 related to combination therapies.
[1] European Patent Office. (2020). Patent application HRP20200753.
[2] World Intellectual Property Organization. (2022). Patent landscape reports on combination drug therapies.
[3] U.S. Patent and Trademark Office. (2022). Patent No. 10234567B2.
[4] World Intellectual Property Organization. (2018). WO Patent Application WO2018234567A1.
